Loading...

Avenue Therapeutics, Inc.

ATXI•NASDAQ
Healthcare
Biotechnology
$0.51
$-0.14(-21.54%)

Avenue Therapeutics, Inc. (ATXI) Company Profile & Overview

Explore Avenue Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Avenue Therapeutics, Inc. (ATXI) Company Profile & Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

SectorHealthcare
IndustryBiotechnology
CEOAlexandra MacLean

Contact Information

https://www.avenuetx.com
781 652 4500
1140 Avenue of the America, New York City, NY, 10036

Company Facts

2 Employees
IPO DateJun 27, 2017
CountryUS
Actively Trading

Frequently Asked Questions

;